INSM (Insmed, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by INSM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-11 | David R Brennan | Director | Sell | — | — |
| 2026-08-19 | MELVIN MD SHAROKY | Director | Sell | — | — |
| 2026-08-12 | Roger Adsett | Chief Operating Officer | MIXED | — | — |
| 2026-08-07 | Martina M.D. Flammer | Chief Medical Officer | MIXED | — | — |
| 2026-08-07 | Martina M.D. Flammer | Chief Medical Officer | MIXED | — | — |
| 2026-07-24 | William Lewis | Chair and CEO | MIXED | — | — |
| 2026-07-10 | William Lewis | Chair and CEO | MIXED | — | — |
| 2026-07-08 | Martina M.D. Flammer | Chief Medical Officer | MIXED | — | — |
| 2026-06-26 | William Lewis | Chair and CEO | MIXED | — | — |
| 2026-06-24 | Michael Alexander Smith | Chief Legal Officer | Sell | — | — |
| 2026-06-24 | Samuele Butera | SVP, GM, Global Respiratory | A | — | — |
| 2026-06-10 | William Lewis | Chair and CEO | Sell | — | — |
| 2026-06-05 | Martina M.D. Flammer | Chief Medical Officer | Sell | — | — |
| 2026-06-05 | William Lewis | Chair and CEO | Sell | — | — |
| 2026-06-05 | Michael Alexander Smith | Chief Legal Officer | Sell | — | — |
| 2026-06-05 | Sara Bonstein | Chief Financial Officer | Sell | — | — |
| 2026-06-05 | Roger Adsett | Chief Operating Officer | Sell | — | — |
| 2026-05-22 | Michael Alexander Smith | Chief Legal Officer | Sell | — | — |
| 2026-05-20 | William Lewis | Chair and CEO | MIXED | — | — |
| 2026-05-15 | William Lewis | Chair and CEO | Sell | — | — |
| 2026-05-15 | LEO LEE | Director | A | — | — |
| 2026-05-15 | Clarissa Desjardins | Director | A | — | — |
| 2026-05-15 | David R Brennan | Director | A | — | — |
| 2026-05-15 | MELVIN MD SHAROKY | Director | A | — | — |
| 2026-05-15 | Michael Alexander Smith | Chief Legal Officer | Sell | — | — |
| 2026-05-15 | Martina M.D. Flammer | Chief Medical Officer | Sell | — | — |
| 2026-05-15 | ELIZABETH M ANDERSON | Director | A | — | — |
| 2026-05-15 | Roger Adsett | Chief Operating Officer | Sell | — | — |
| 2026-05-15 | CAROL SCHAFER | Director | A | — | — |
| 2026-05-15 | Sara Bonstein | Chief Financial Officer | Sell | — | — |
| 2026-05-13 | Martina M.D. Flammer | Chief Medical Officer | MIXED | — | — |
| 2026-05-06 | William Lewis | Chair and CEO | MIXED | — | — |
| 2026-04-17 | William Lewis | Chair and CEO | MIXED | — | — |
| 2026-04-08 | William Lewis | Chair and CEO | MIXED | — | — |
| 2026-04-03 | Roger Adsett | Chief Operating Officer | MIXED | — | — |
| 2026-03-31 | Michael Alexander Smith | Chief Legal Officer | MIXED | — | — |
| 2026-03-20 | William Lewis | Chair and CEO | MIXED | — | — |
| 2026-03-05 | MELVIN MD SHAROKY | Director | G | — | — |
| 2026-03-05 | William Lewis | Chair and CEO | MIXED | — | — |
| 2026-02-27 | MELVIN MD SHAROKY | Director | G | — | — |
| 2026-02-25 | David R Brennan | Director | G | — | — |
| 2026-02-25 | Michael Alexander Smith | Chief Legal Officer | MIXED | — | — |
| 2026-02-23 | William Lewis | Chair and CEO | MIXED | — | — |
| 2026-02-11 | William Lewis | Chair and CEO | MIXED | — | — |
| 2026-02-11 | DAVID W J MCGIRR | Director | G | — | — |
| 2026-02-06 | Martina M.D. Flammer | Chief Medical Officer | Sell | — | — |
| 2026-02-04 | Martina M.D. Flammer | Chief Medical Officer | MIXED | — | — |
| 2026-02-04 | Michael Alexander Smith | Chief Legal Officer | Sell | — | — |
| 2026-02-04 | William Lewis | Chair and CEO | Sell | — | — |
| 2026-02-04 | Sara Bonstein | Chief Financial Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chair and CEO | 503,682 | — |
| — | Director | 320,802 | — |
| — | Chief Operating Officer | 257,624 | — |
| — | Director | 251,504 | — |
| — | President, CEO and Chairman | 182,668 | — |
| — | Chief Legal Officer | 149,985 | — |
| — | Chief Commercial Officer | 140,935 | — |
| — | Director | 99,238 | — |
| — | Director | 97,723 | — |
| — | Director | 73,337 | — |
| — | Director | 71,288 | — |
| — | Director | 69,495 | — |
| — | Chief Financial Officer | 69,082 | — |
| — | Director | 66,622 | — |
| — | Director | 62,197 | — |
| — | Director | 62,034 | — |
| — | Chief Medical Officer | 60,486 | — |
| — | Executive VP & CFO | 59,729 | — |
| — | Director | 57,971 | — |
| — | Chief Compliance Officer | 52,553 | — |
| — | President Follow-on Biologics | 47,716 | — |
| — | SVP, Gen. Counsel & Corp Sec. | 45,000 | — |
| — | Chief People Strategy Officer | 41,754 | — |
| — | Chief Legal Officer | 37,648 | — |
| — | Executive Vice President & CMO | 37,014 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the INSM quote page; the site-wide leaderboard is on the insider transactions hub.